# EDGAR Filing Document

**Accession Number:** 0001544227
**File Stem:** 0001193125-26-133140
**Filing Date:** 2026-3
**Character Count:** 10771
**Document Hash:** fe870e716b4028bd6cf230bbb51b8f0a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-133140.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001193125-26-133140

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**EFFECTIVENESS DATE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tempest Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001544227
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 451472564
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294732
- **FILM NUMBER:** 26816672

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY
- **STREET 2:** SUITE 400
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 415-798-8589

**MAIL ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY
- **STREET 2:** SUITE 400
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Millendo Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20181207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OvaScience, Inc.
- **DATE OF NAME CHANGE:** 20120308

**As filed with the U.S. Securities and Exchange Commission on March 31, 2026** 

**Registration No. 333-294732** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1** 

**TO** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Tempest Therapeutics, Inc.
**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **45-1472564** |
| **(State or other jurisdiction of<br>Incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |

---

**2000 Sierra Point Parkway, Suite 400** 

**Brisbane, California 94005** 

**(415) 798-8589** 

**(Address of principal executive offices) (Zip code)** 

**Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan** 

**Tempest Therapeutics, Inc. Amended and Restated 2019 Employee Stock Purchase Plan** 

**(Full titles of the plans)** 

**Matthew Angel** 

**Chief Executive Officer** 

**Tempest Therapeutics, Inc.** 

**2000 Sierra Point Parkway, Suite 400** 

**Brisbane, California 94005** 

**(415) 798-8589** 

**(Name, address and telephone number, including area code, of agent for service)** 

***Copies to:***

**Laura Berezin** 

**Jaime Chase** 

**Cooley LLP** 

**1700 Seventh Avenue, Suite 1900** 

**Seattle, Washington 98101** 

**(206) 452-8700** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

------

**EXPLANATORY NOTE** 

This Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (File No. <u>333-294732</u>), originally filed by Tempest Therapeutics, Inc. (the "Company") with the Securities and Exchange Commission on March 30, 2026, is being filed solely to correct Exhibit 23.2, the Consent of Independent Registered Public Accounting Firm. The original filing mistakenly included a version of the consent with an incorrect date for the report of Ernst & Young LLP with respect to the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. No other changes have been made to the Registration Statement.

------

**Item 8. Exhibits** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| <br>**Exhibit <br>Number** | <br>**Description** | **Schedule<br>Form** | **File<br>Number** | **Exhibit** | <br>**Filing<br>Date** |
| 4.1 | [Restated Certificate of Incorporation of the Registrant, as amended](http://www.sec.gov/Archives/edgar/data/1544227/000155837019005038/mlnd-20190331ex31b53fa83.htm) | 10-Q | 001-35890 | 3.1 | 5/15/2019 |
| 4.2 | [Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 24, 2021](http://www.sec.gov/Archives/edgar/data/1544227/000119312521201157/d196630dex31.htm) | 8-K | 001-35890 | 3.1 | 6/28/2021 |
| 4.3 | [Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 25, 2021](http://www.sec.gov/Archives/edgar/data/1544227/000119312521201157/d196630dex32.htm) | 8-K | 001-35890 | 3.2 | 6/28/2021 |
| 4.4 | [Certificate of Designation of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware on October 10, 2023](http://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/d547808dex31.htm) | 8-K | 001-35890 | 3.1 | 10/11/2023 |
| 4.5 | [Amended and Restated Bylaws of the Registrant](http://www.sec.gov/Archives/edgar/data/1544227/000119312521281694/d222030dex31.htm) | 8-K | 001-35890 | 3.1 | 9/4/2021 |
| 4.6 | [Rights Agreement, dated as of October 10, 2023, between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C](http://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/d547808dex41.htm) | 8-K | 001-35890 | 4.1 | 10/11/2023 |
| 4.7 | [Amendment No. 1, dated as of October 9, 2024, to Rights Agreement, dated as of October 10, 2023, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., as rights agent](http://www.sec.gov/Archives/edgar/data/1544227/000119312524235598/d877681dex41.htm) | 8-K | 001-35890 | 4.1 | 10/10/2024 |
| 4.8 | [Amendment No. 2, dated as of December 5, 2024, to Rights Agreement, dated as of October 10, 2023, as amended, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., as rights agent](http://www.sec.gov/Archives/edgar/data/1544227/000119312524272464/d899818dex41.htm) | 8-K | 001-35890 | 4.1 | 12/06/2024 |
| 5.1 | [Opinion of Cooley LLP](http://www.sec.gov/Archives/edgar/data/1544227/000119312526132033/d90534dex51.htm) | S-8 | 333-294732 | 5.1 | 3/30/2026 |
| 23.1 | [Consent of Cooley LLP (included in Exhibit 5.1).](http://www.sec.gov/Archives/edgar/data/1544227/000119312526132033/d90534dex51.htm) | S-8 | 333-294732 | 23.1 | 3/30/2026 |
| 23.2\* | [Consent of Ernst & Young LLP, independent registered public accounting firm](d90534dex232.htm) |  |  |  |  |
| 24.1 | [Power of Attorney (included on the signature page of this Form S-8)](http://www.sec.gov/Archives/edgar/data/1544227/000119312526132033/d90534ds8.htm#sig) | S-8 | 333-294732 | 24.1 | 3/30/2026 |
| 99.1 | [Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1544227/000095017023041429/tpst-ex10_1.htm) | 10-Q | 001-35890 | 10.1 | 8/10/2023 |
| 99.2 | [Amendment No. 1 to Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1544227/000119312526130490/tpst-ex10_12.htm) | 10-K | 001-35890 | 10.12 | 3/30/2026 |
| 99.3 | [Tempest Therapeutics, Inc. 2019 Employee Stock Purchase Plan](http://www.sec.gov/Archives/edgar/data/1544227/000119312522177053/d370249dex102.htm) | 8-K | 001-35890 | 10.2 | 6/21/2022 |
| 107 | [Filing Fee Table](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1544227/000119312526132033/d90534dexfilingfees.htm) | S-8 | 333-294732 | 107 | 3/30/2026 |

---

\* Filed herewith

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Brisbane, State of California, on March 31, 2026.

---

| | |
|:---|:---|
| **Tempest Therapeutics, Inc.** | **Tempest Therapeutics, Inc.** |
| By: | /s/ Matthew Angel |
| Name: | Matthew Angel |
| Title: | President and Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Matthew Angel<br> Matthew Angel | President, Chief Executive Officer and Director<br> *(Principal Executive Officer)* | March 31, 2026 |
| /s/ Nicholas Maestas<br> Nicholas Maestas | Chief Financial Officer and Head of Corporate Strategy<br> *(Principal Financial Officer)* | March 31, 2026 |
| /s/ Justin Trojanowski<br> Justin Trojanowski | Corporate Controller, Treasurer <br> *(Principal Accounting Officer)* | March 31, 2026 |
| \*<br> Stephen Brady | Chairman of the Board of Directors | March 31, 2026 |
| \*<br> Christine Pellizzari | Director | March 31 2026 |
| \*<br> Michael Raab | Director | March 31, 2026 |
| \*<br> Ronit Simantov | Director | March 31, 2026 |

---

---

| | |
|:---|:---|
| \*By: | /s/ Matthew Angel |
| Name: | Matthew Angel |
|  | Attorney-in-fact |

---

## Exhibit 23.2

**Exhibit 23.2** 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan and the Tempest Therapeutics, Inc. Amended and Restated 2019 Employee Stock Purchase Plan of our report dated March 30, 2026, with respect to the consolidated financial statements of Tempest Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Chicago, Illinois

March 30, 2026